{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Argentina Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/ar/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/ar/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Argentina, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHG"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/2eb38e8e-60a9-419b-aea8-e14f51cf97d9/"}]}}, {"id": "source:244e49ff005a068ab08a7c98d6917683f94fa19dc5eb742699689f75b3548f59", "url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "title": "Koninklijke Philips (ENXTAM:PHIA) Following Exor Stake Update Still Looks Close To Fair Value", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance arrangements remain unchanged. See our latest analysis for Koninklijke Philips. At a share price of \u20ac23.19, Koninklijke Philips has seen a small pullback over the past month with a 1 month share price return of a 3.74% decline, although the 3 year total shareholder return of 31.21% points to a stro", "date_published": "2026-08-13T17:11:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHG"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/2eb38e8e-60a9-419b-aea8-e14f51cf97d9/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:1e0cde33e45bc82a30375dfc4c94e9b07cb308ddf22aac26c5b00ca8d2be89dd", "url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "external_url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "title": "Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar", "content_text": "Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment\u2014and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading", "date_published": "2026-08-13T04:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:19c448bd17978ba69542b6669c5c4089a3b8247df77ddaecd09b8b118d2b7c96", "url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "title": "Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real world metabolic health studies using anonymized Lingo data combined with Google's AI ", "date_published": "2026-08-12T21:13:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the ", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:cb1fb61e2d7b4c9de7e8f3ba544e3579767d3406ea22a6d11486614a7eb1e9aa", "url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "title": "DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?", "content_text": "DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's 6.9% decline and S&P 500 Index's 13.1% gain. The second-quarter performance reflected recovery, with revenues rising 13% year over year and organic growth reaching 12%. U.S. revenues increased 11%, while international revenues jumped 19%, reflecting broader reimbursement, market-sha", "date_published": "2026-08-12T18:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:0f3f921f4e754d1dc87f0170b5d5e6487b23b1075953275044ad300b7bd58823", "url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "title": "Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?", "content_text": "DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels. DexCom's Q2 Results Reset the 2026 Baseline DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% yea", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:3ea6e701ff7683fcac8c3f9bcb8cf44f16546528c61754b8293901a2b441debc", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "date_published": "2026-08-12T17:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:236f34736a111bb242258345d7e1c88edda917f48b269c364f2bb5538f36f2f3", "url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "title": "Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis", "content_text": "\"We Give Blood\" brings together all 18 Big Ten\u00ae schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between", "date_published": "2026-08-12T13:14:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:578a0f2db601796dd5dbafacfdc29748269b258cca81fd8d2fed95ac1f7dea2e", "url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "external_url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "title": "Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, earnings-based multiples still screen the shares as undervalued, which sets up a debate over how much upside is left from here. A 20.8% return over three years points to steady value creation for Medtronic shareholders, not a rapid rerating. Progress in highe", "date_published": "2026-08-12T02:35:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:fa608ad6fc2e675f9bf0941c2b6f8903ea4ae049f70b1537756fbf640ec6981e", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "\u00bfPuede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsi\u00f3n Anual?", "content_text": "\u00bfPuede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsi\u00f3n Anual?", "date_published": "2026-08-12T00:22:46+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:72aa665eb60e17fce872a03c6128eeb8ba22d1c15148e33faccad6e4ee9ef7cb", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "\u00bfLa revisi\u00f3n al alza de Medtronic (MDT) por parte de UBS, tras un s\u00f3lido crecimiento impulsado por el sector card\u00edaco, acaba de cambiar su perspectiva de inversi\u00f3n?", "content_text": "\u00bfLa revisi\u00f3n al alza de Medtronic (MDT) por parte de UBS, tras un s\u00f3lido crecimiento impulsado por el sector card\u00edaco, acaba de cambiar su perspectiva de inversi\u00f3n?", "date_published": "2026-08-11T22:54:58+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:7cd8b308fd1ba8ee1d12f8541454ba69d33a2e88a8e29e6993906d377fa06a13", "url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-meta-texas-203100631.html", "title": "Top Research Reports for Meta, Texas Instruments & CrowdStrike", "content_text": "Tuesday, August 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Texas Instruments Inc. (TXN) and CrowdStrike Holdings, Inc. (CRWD), as well as a micro-cap stock Weyco Group, Inc. (WEYS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team t", "date_published": "2026-08-11T20:31:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:87f3f3c3d7a52b0e838831f823951d5707a7816c1b703a90b5d58c54f9f329f6", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "title": "Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth in a decade, supported by its cardiac portfolio and new product launches. See our latest analysis for Medtronic. Over the past quarter Medtronic has picked up momentum, with a 90 day share price return of 16.39% and a 30 day gain of 6.61%, while the 1 year total shareholder return is close to flat and the 5", "date_published": "2026-08-11T19:15:12+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:a93731d0c9c40eb23dcb21e7d72b4b1b03117182e350815ead3bff07ebac932a", "url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "external_url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "title": "Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations", "content_text": "Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet, containing 13.7 API crude, with Abbott saying the Ubaque trend extends across the northern part of the Tapir Block, supporting further development drilling. Wit", "date_published": "2026-08-11T17:41:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:1669df33eaba3e6eee9714c010f314c05d1e8287e8ce389932ee77aaead1dfe1", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "content_text": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "date_published": "2026-08-11T13:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:9b0747406a31f261a432fba0c0e5eb1aba2c71244b46ea5c19d6bb0ddefce0e0", "url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "title": "Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI", "content_text": "Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswi", "date_published": "2026-08-11T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:a7cc9f369a9e2ed3cd16858a5d3b642a5276c8871db9133dde26f3c04ec07faa", "url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "external_url": "https://finance.yahoo.com/healthcare/articles/versa-vascular-appoints-bill-shields-120000282.html", "title": "Versa Vascular Appoints Bill Shields as Chief Executive Officer", "content_text": "Company Expands Series C Financing to $42M SANTA CRUZ, Calif., August 11, 2026--(BUSINESS WIRE)--Versa Vascular, Inc., a pioneering medical device company dedicated to transforming tricuspid valve disease treatment, announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is retiring and will remain an advisor to the company. Shields spent the last 15 years with Medtronic's structural heart franchise, most recently as Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division, where he spent seven years leading prod", "date_published": "2026-08-11T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:8e160b0a5f60e252ab93dfa8f9231797d251b8f53394b88e95bd7f3fe4407139", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-piles-8-billion-debt-110500324.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbvie-piles-8-billion-debt-110500324.html", "title": "AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?", "content_text": "AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, to fund the acquisition of the biotech company, AbbVie is taking on significant debt, which concerns some analysts. The payoff, AbbVie says, likely won't come for six years, with the deal not expected to boost adjusted earnings per share (EPS) until 2032. Missed Nvidia in 2009? This Rare Signal", "date_published": "2026-08-11T11:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:1e0e00363db074638cbc860140fc49273515a220d295b2895102a2c88136eada", "url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "title": "Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players", "content_text": "Company Logo Pulsed Field Ablation MarketPulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035\" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, representing a compound annual growth rate of 18.4% during the forecast period. Rising atr", "date_published": "2026-08-11T09:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:d56bac5c876b80aeeca49e31e5dfbdb723366f1c47826404898c7d2ffbcfb38b", "url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "external_url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "title": "Royal Philips And Exor Update Long-Term Relationship Agreement", "content_text": "(RTTNews) - Royal Philips (PHG), a health technology company, and Exor N.V., an investment company, announced that they have agreed to update their long-term relationship agreement. Royal Philips provides image-guided therapy, diagnostic imaging, ultrasound, monitoring, and enterprise informatics and made approximately 18 billion euros in sales in 2025. Exor is the largest shareholder in companies including Ferrari, Philips, CNH and Stellantis. In August 2023, Royal Philips and Exor entered into a relationship agreement, under which Exor bought a 15% shareholding in Royal Philips to provide co", "date_published": "2026-08-11T08:14:10+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "PHG"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/2eb38e8e-60a9-419b-aea8-e14f51cf97d9/"}]}}, {"id": "source:1c8e1137cbdd39b6aea8b289794d24a367c007eba5a577b44e7c22e467624381", "url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "title": "Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?", "content_text": "Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term ", "date_published": "2026-08-10T22:46:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:99a501eedeb3958ebe6a4d1351adb2e9a43c8bc2f34e87f9aa19ae7d64103286", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "date_published": "2026-08-10T22:36:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:1810cfe780396af526d2dcbea72cac0b1203480f9a77542bd5f76951829891ea", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-increases-despite-market-214502376.html", "title": "Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know", "content_text": "In the latest close session, Medtronic (MDT) was up +2.58% at $89.41. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 0.32%. The medical device company's stock has climbed by 3.92% in the past month, exceeding the Medical sector's loss of 0.38% and the S&P 500's gain of 3.42%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. On that day, Medtronic is projected to report earnings of $1.39 per share, which wo", "date_published": "2026-08-10T21:45:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:d3ab2b7502c0abaac5cde1db78f3d61c3eea5a4004021eb3d7b5a05c0c8bffc5", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "date_published": "2026-08-10T20:49:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:d010ce60e0526c4316a61eeda2801e4969c0e0ffa92f85fbf34fe5b5ce5e3794", "url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "external_url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-reports-second-quarter-201200454.html", "title": "Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates", "content_text": "Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial (\"BACKBEAT Trial\"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met. Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand. Company to host R&D Day on November", "date_published": "2026-08-10T20:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:390765aa7addb2236810f0ab23ac9e6d6081e06b54be92e59ed0289d5d56666d", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "title": "Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?", "content_text": "Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. According to Fortune Business Insights, the global medical devices market was valued at $572.31 billion in 2025 and is projected to increase from $604.99 billion in 2026 to $1.03 trillion by 2034, reflecting a CAGR of 6.9% over the forecasted period. Given this favorable industry backdrop, Ab", "date_published": "2026-08-10T14:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "content_text": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:c2cae5d842d00a04b75cba6303708340781f4106ae510a70c537c7440b2dcae8", "url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/said-4-dividend-aristocrats-could-134539654.html", "title": "We Said These 4 Dividend Aristocrats Could Soar. Here\u2019s How They Did, Plus 3 New Picks.", "content_text": "Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of increases and BF-A its 82nd. ALB, MDT, and SWK offer cyclical, defensive, and industrial dividend plays, each with dramatically improved free cash flow coverage heading into fiscal 2027. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to ", "date_published": "2026-08-10T13:45:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:6a7f281ce2bb1823c3712f316b0761ba9ab889f185b0fe61e52d14c509cd0ab6", "url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/varex-imaging-vrex-q3-earnings-121505093.html", "title": "VAREX IMAGING (VREX) Q3 Earnings Beat Estimates", "content_text": "VAREX IMAGING (VREX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +40.91%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.21, delivering a surprise of -4.55%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. VAREX IMAGING, which belongs to the ", "date_published": "2026-08-10T12:15:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:455f96e15db4bb8b0af01b95c9642b11502fa4455a603549f01df4629a717c6c", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "title": "Is Medtronic (MDT) Becoming a Turnaround Story?", "content_text": "UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a \"turnaround\" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth Bull case One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and", "date_published": "2026-08-09T23:43:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:b7ca0134fa3006e393c4a3afef70e44399482653df0108e642db1ab9ec2c324f", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5ELURCLVZlel9fZWVIa0x4NVBRRnZ6RDJ5Z2h1MERkVUotcmx3QVFYMTRobUg1c1R1blMwX3lXcFBuazdkci0tZUZNRktpcmVjTGRoMUxHN3FmcDhzV3c4RUJMUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5ELURCLVZlel9fZWVIa0x4NVBRRnZ6RDJ5Z2h1MERkVUotcmx3QVFYMTRobUg1c1R1blMwX3lXcFBuazdkci0tZUZNRktpcmVjTGRoMUxHN3FmcDhzV3c4RUJMUQ?oc=5", "title": "Noticias de acciones de Medtronic PLC (MDT)", "content_text": "Noticias de acciones de Medtronic PLC (MDT)", "date_published": "2026-08-09T07:21:37+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "external_url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "content_text": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "date_published": "2026-08-08T21:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:0228fda7a01299989d2cdb3dc45402850ea86f8309b6e3713d2645b01b96fb53", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "external_url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "content_text": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "date_published": "2026-08-08T16:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:053419f368676f2469ea023f4e0a3e1b2e945ed3c1994c5c34801aa4bc954f69", "url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "title": "Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder re", "date_published": "2026-08-08T16:11:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:8a4a791cca70b4beebb809c5f2a1ed4b675fe78145cbd17af5a9f36e22a31096", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "title": "Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, which highlights its potential clinical impact. This broader regulatory progress could influence Medtronic's position in cardiac arrhythmia care across international markets. As cardiac care technology evolves and Medtronic advances ", "date_published": "2026-08-08T02:09:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:9028e6ea75e478504b813641a008ee39656a652446277bc278a9162de577c10d", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNWmtUMGkwa28xZWpYVml1MEdySDJSRzhJUFpSN19EbjJ5Sk45aXVhb1dic2V1T1ZVc1pQdm93UW1iWnZtTUw2aHpJVHNjbFNiclFxZmIxTHR4Rm5zM0w1UFQxRTFoczJ5QUNwUlZ3ZHVDQzZ5a09ld01yek9xbG5Nd0xHYkFLQmZUd3NqeFRMU0FRSUZpaHNyZmJvc2xhR29SdjBmcXNtOTRvM2RqWVpBRlFfakRzVzFINUQyYk03aUJUYXh2SHVWZ2FNY0VMcUkyR3pZVGNYRWFpOEQzZkpDSVFsZWcxd1BqdGVB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNWmtUMGkwa28xZWpYVml1MEdySDJSRzhJUFpSN19EbjJ5Sk45aXVhb1dic2V1T1ZVc1pQdm93UW1iWnZtTUw2aHpJVHNjbFNiclFxZmIxTHR4Rm5zM0w1UFQxRTFoczJ5QUNwUlZ3ZHVDQzZ5a09ld01yek9xbG5Nd0xHYkFLQmZUd3NqeFRMU0FRSUZpaHNyZmJvc2xhR29SdjBmcXNtOTRvM2RqWVpBRlFfakRzVzFINUQyYk03aUJUYXh2SHVWZ2FNY0VMcUkyR3pZVGNYRWFpOEQzZkpDSVFsZWcxd1BqdGVB?oc=5", "title": "Abbott Laboratories (ABT) Stock Analysis: Navigating a 12% Upside Potential Amid Robust Healthcare Offerings", "content_text": "Abbott Laboratories (ABT) Stock Analysis: Navigating a 12% Upside Potential Amid Robust Healthcare Offerings", "date_published": "2026-08-03T09:19:05+00:00", "authors": [{"name": "DirectorsTalk Interviews"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:83cf700861cd9bb250a5fe6c48f6220aa54ffc700d8123d4706ecf50a625f2da", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORURMdzZDU0xHUHFJRV85WDVHWG1RNE4zc19zekhvZEpxLVZFTy1xQmN4QnVhbkdQRW5XUTViWENIRHJkdWh6cng2VGhXWlNuMnFmeG9zYUNKX1lCendPLXJQSkFPQjlpZk9MMGFlMnBkbzU1c2RRczVmTXg2MWVTcXpoTTNOMDF1cl9uOExmWDBsOFpiOG00RWdzS3d5emtjeklkb2lFYWg2YUFXSFZiRHoxWHF5a0U?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORURMdzZDU0xHUHFJRV85WDVHWG1RNE4zc19zekhvZEpxLVZFTy1xQmN4QnVhbkdQRW5XUTViWENIRHJkdWh6cng2VGhXWlNuMnFmeG9zYUNKX1lCendPLXJQSkFPQjlpZk9MMGFlMnBkbzU1c2RRczVmTXg2MWVTcXpoTTNOMDF1cl9uOExmWDBsOFpiOG00RWdzS3d5emtjeklkb2lFYWg2YUFXSFZiRHoxWHF5a0U?oc=5", "title": "Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance", "content_text": "Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance", "date_published": "2026-07-18T06:35:04+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:2ba86ba0b5673ae268f50814f9693f2e831952a62e7ab927d7ce26085d7b788c", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcC12RXF3TWtLa2dxd0FlZ1E5LUlteW5IRUhRZ21DWDlmaDFPU2hfWkhtbWZjNnp5OFp4cmVZS29qY1Rkemk0bHlJN3ptVFNBLS1YUU9QRERfc0VpamJPWWkzUUwwdkxQWm4tZVJWRDI2ekV5ZnIyQlZzRVRMdUZjUk1vcl8zWUtITk14Nzl6dzJMYlRBNW9lNDVhS09OTUFEY3lYNTFRbHJDd1E0b3FqTjJKa1hVQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcC12RXF3TWtLa2dxd0FlZ1E5LUlteW5IRUhRZ21DWDlmaDFPU2hfWkhtbWZjNnp5OFp4cmVZS29qY1Rkemk0bHlJN3ptVFNBLS1YUU9QRERfc0VpamJPWWkzUUwwdkxQWm4tZVJWRDI2ekV5ZnIyQlZzRVRMdUZjUk1vcl8zWUtITk14Nzl6dzJMYlRBNW9lNDVhS09OTUFEY3lYNTFRbHJDd1E0b3FqTjJKa1hVQQ?oc=5", "title": "Abbott eleva su previsi\u00f3n de beneficio por acci\u00f3n para 2026", "content_text": "Abbott eleva su previsi\u00f3n de beneficio por acci\u00f3n para 2026", "date_published": "2026-07-16T12:06:23+00:00", "authors": [{"name": "MarketScreener Espa\u00f1a"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:d1cc87bba57f3f7f34bb489e1abb23010b67294025425a05387f2140bfc52927", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQOGtMR2xOYkd6Zk5hT01kczJ1ak0xdEZJR0l6akc0VDFPM1htZGJIU29JNmtmZUdDMEh0cVAtSHdiUnpaSEZjaUY3enlFaWpuVmtNYVlUV2oyLXo5WnBsT0hfelJ6LXFNcFhvbFZqYjdid1R5UC0yVlE3SXU3clBZN0EtY19FTExBUTY2cVNIaXdCS2RXeHJFbkVHNjI0MEJXMXhKazJyUzZWckgyWWVmTU1iQ2p3U1JJbjFZVjA2bktBeVExR2g1SzBtSnh6OFBMUmc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQOGtMR2xOYkd6Zk5hT01kczJ1ak0xdEZJR0l6akc0VDFPM1htZGJIU29JNmtmZUdDMEh0cVAtSHdiUnpaSEZjaUY3enlFaWpuVmtNYVlUV2oyLXo5WnBsT0hfelJ6LXFNcFhvbFZqYjdid1R5UC0yVlE3SXU3clBZN0EtY19FTExBUTY2cVNIaXdCS2RXeHJFbkVHNjI0MEJXMXhKazJyUzZWckgyWWVmTU1iQ2p3U1JJbjFZVjA2bktBeVExR2g1SzBtSnh6OFBMUmc?oc=5", "title": "Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings", "content_text": "Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings", "date_published": "2026-06-29T07:00:00+00:00", "authors": [{"name": "DirectorsTalk Interviews"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:7d91a8a3bcbdd7860881df558b0fcd8196e811e94fc69d1ff5c7d8f0705eb6c3", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOSGhQSzBEUFdrTlU5Y0w0elRzektxb1lUdjdiWHB3bzllU1RSSmJFbjVDaWtJUThuTHNTN05yTHZQSUhNVFNDSDV2RkJHUGN1SS01S3ozcTB5aVEyVmdqd0V2R1VxTHdnSFFEUmdiTV9CN1pMdzVPbVExcmZSWE50YkZ3TzdLMlR0eXN5M2I3MFNZSngzWWdsOGhn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOSGhQSzBEUFdrTlU5Y0w0elRzektxb1lUdjdiWHB3bzllU1RSSmJFbjVDaWtJUThuTHNTN05yTHZQSUhNVFNDSDV2RkJHUGN1SS01S3ozcTB5aVEyVmdqd0V2R1VxTHdnSFFEUmdiTV9CN1pMdzVPbVExcmZSWE50YkZ3TzdLMlR0eXN5M2I3MFNZSngzWWdsOGhn?oc=5", "title": "Medtronic stock holds steady as Q4 FY26 revenue exceeds consensus", "content_text": "Medtronic stock holds steady as Q4 FY26 revenue exceeds consensus", "date_published": "2026-06-18T07:00:00+00:00", "authors": [{"name": "Traders Union"}], "tags": ["Earnings", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:7f9cb917e907a7513d01b11a7989689854baae5aba066a986fd65d60d2dbe0fb", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVl9sSjh4Y1JBem4yNnUzVmhXVjdqSktheVhaMjRZOGpreWpRdjJfbmoyM1RIbHdOSGhRT2E4UlZCY3p2dm9XZ2FTa0tLMllMX0dWNHU0MFpSN1pzZlpTVy1VVk5IUWVBd3pvQkZ0OFBkV2hKdkExNlJVLUxNRExPOHZCLUMxeFdfcUx2dVdEVzZDVDZYcDJ3ZS1abjVyd0RFWUJNeA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVl9sSjh4Y1JBem4yNnUzVmhXVjdqSktheVhaMjRZOGpreWpRdjJfbmoyM1RIbHdOSGhRT2E4UlZCY3p2dm9XZ2FTa0tLMllMX0dWNHU0MFpSN1pzZlpTVy1VVk5IUWVBd3pvQkZ0OFBkV2hKdkExNlJVLUxNRExPOHZCLUMxeFdfcUx2dVdEVzZDVDZYcDJ3ZS1abjVyd0RFWUJNeA?oc=5", "title": "Abbott Laboratories stock gains as Norges Bank acquires new institutional position", "content_text": "Abbott Laboratories stock gains as Norges Bank acquires new institutional position", "date_published": "2026-06-04T07:00:00+00:00", "authors": [{"name": "Traders Union"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:9084a531b8d5884f1e3932c7bf183a3cdc26cd0fbbf3b90eff5d81a88f31f00c", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQd0JhNG5xVzA0dDg5bk5YelJfeU16WjVPbndDLXRLUHQwNFZqdEdsUnZMV0tMa0VqejY3XzdXWWZhUVotSEhjLWFFRlFGcjZpSmE1d1Y5Q0hVb0VjeUo1RUJXV1d5T0dnVjkxdmU1aVE0dkUwOUpOLXUycm56LUdCVWMzWUg1Q21zWU5oTjJPNG0zZkNrT293UF93U1N3Ynlmd1lPdjdXUmlJeDk2ZVVsTzVvYmJJaFFFNlh0MlhmUV9mTTN2OGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQd0JhNG5xVzA0dDg5bk5YelJfeU16WjVPbndDLXRLUHQwNFZqdEdsUnZMV0tMa0VqejY3XzdXWWZhUVotSEhjLWFFRlFGcjZpSmE1d1Y5Q0hVb0VjeUo1RUJXV1d5T0dnVjkxdmU1aVE0dkUwOUpOLXUycm56LUdCVWMzWUg1Q21zWU5oTjJPNG0zZkNrT293UF93U1N3Ynlmd1lPdjdXUmlJeDk2ZVVsTzVvYmJJaFFFNlh0MlhmUV9mTTN2OGc?oc=5", "title": "Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside", "content_text": "Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside", "date_published": "2026-05-25T07:00:00+00:00", "authors": [{"name": "DirectorsTalk Interviews"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:3718064a7c0f49a7c7bf8bfdc0f0c99c6befba5fdaf9c1c1f9020946bbdca017", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdmo4V3NlWG1xTVBPZk1MWnBVOXRSempmSzVCSU5fV2FKTjJSYURsXzV3QjREZmJNSXNxc3NlbDl5d0V3eE5iWXRrWkh5YWI4UFZuQWs1Y3BCS09oNjZRZ0hlX29CT3FweGJPLWFkTndKUF85N05aaEYxVm5IclJGQTlTVVBzaG80Q0lWLVJEUkhuVElkQlE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNdmo4V3NlWG1xTVBPZk1MWnBVOXRSempmSzVCSU5fV2FKTjJSYURsXzV3QjREZmJNSXNxc3NlbDl5d0V3eE5iWXRrWkh5YWI4UFZuQWs1Y3BCS09oNjZRZ0hlX29CT3FweGJPLWFkTndKUF85N05aaEYxVm5IclJGQTlTVVBzaG80Q0lWLVJEUkhuVElkQlE?oc=5", "title": "Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics", "content_text": "Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics", "date_published": "2026-05-22T07:00:00+00:00", "authors": [{"name": "IndexBox"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:ca1c1ada2637614566366df149aa9d244ad6723e892e843545b7d8243856895f", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPb0lTUnN2VjBKM1NKQW9QWmdJT3V3NG4tX2tNNVhYSHpjeGk5cXQ0MUxhSmZsU0c5MVE4ZUs1ZTFDdUI0MWJxT3pfSWthazlkT0JuNTV6REF3Q2Zfb0NKUklIelE2bmRmS0VrZ0k3ay1ZSTBFNUdmTTBaTUJWRkJlQWJlY3dTVWwxOW9UbEpFbEZXUVNGaWpUUTFpUTVWTjRTb2FDSlZncmdhbE5jQjZYcnhLdXg2dw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPb0lTUnN2VjBKM1NKQW9QWmdJT3V3NG4tX2tNNVhYSHpjeGk5cXQ0MUxhSmZsU0c5MVE4ZUs1ZTFDdUI0MWJxT3pfSWthazlkT0JuNTV6REF3Q2Zfb0NKUklIelE2bmRmS0VrZ0k3ay1ZSTBFNUdmTTBaTUJWRkJlQWJlY3dTVWwxOW9UbEpFbEZXUVNGaWpUUTFpUTVWTjRTb2FDSlZncmdhbE5jQjZYcnhLdXg2dw?oc=5", "title": "Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT): Three Dividend Healthcare Stocks to Consider in 2026", "content_text": "Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT): Three Dividend Healthcare Stocks to Consider in 2026", "date_published": "2026-05-20T07:00:00+00:00", "authors": [{"name": "parameter.io"}], "tags": ["Capital return", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}]}